MedPath

Is There a Role for Mechanical Stimulation in Ovarian Follicular Activation?

Recruiting
Conditions
IVF
Infertility, Female
Premature Ovarian Failure
Interventions
Procedure: Ovarian puncture
Other: Hormonal blood Test
Diagnostic Test: Transvaginal ultrasound
Registration Number
NCT04390308
Lead Sponsor
ART Fertility Clinics LLC
Brief Summary

Premature ovarian failure (POI) is a loss of normal function before age 40, leading to infertility and hypoestrogenism. About 1% of women younger than 40 years old and 0.1% before 30 are affected. Most patients already had impaired or complete loss of fecundity when diagnosed. Hence, the treatment of POI is particularly tough. Currently, no optimal regimen exists to ameliorate ovarian function.

Detailed Description

In women, the non-growing population of follicles that comprise the ovarian reserve is determined at birth and serves as the reservoir for future fertility. This reserve of dormant, primordial follicles and the mechanisms controlling their selective activation which constitute the committing step into folliculogenesis are essential for determining fertility outcomes in women.

While POI is sometimes called premature menopause, it is not identical with menopause. Women with POI may still have occasional irregular periods and may even occasionally achieve a pregnancy. Symptoms of POI include irregular menses or amenorrhea, infertility, hypoestrogenic symptoms and decreased libido. POI may be caused by chromosomal defects such as mosaic Turner's syndrome, exposure to toxins (chemotherapy or radiation), autoimmunity, genetic factors (FMR1) and other unknown factors.

Recently, new promising approaches have emerged for infertility treatment in patients with POI, which are based on arousing the still available primordial follicle pool. It is supposed that these techniques activate dormant primordial follicles using a combination of mechanical signaling and biochemical factors. The hypothesis that mild local ovarian injury, such as ovarian puncture, which is a usual procedure in an IVF center with minimal side effects, might exert a similar favorable effect in women with POI arouses our curiosity.

Different groups have published case series of ovarian procedures, injecting substances in the ovaries (A-PRP) or ovarian biopsies / scratch in infertile patients with low ovarian reserve (LOR) or/and patients with POF. However, those studies were underpowered, including not enough number of cases, with variable inclusion criteria and reporting results with very low scientific evidence. Furthermore, the mechanical effect of injecting the ovary should be taken into consideration during the evaluation of these patients, yet it might improve the ovarian function as well.

There are no previous randomized controlled trials considering a procedure as ovarian puncture, which is easier and accessible at any fertility center.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
70
Inclusion Criteria
  • Signed and dated informed consent
  • Women 40 years of age and younger with documented primary ovarian insufficiency (12).
  • Normal Karyotype
  • BMI </= 35 kg/m2
  • Oligo/amenorrhea for at least 4 months
  • FSH > 25 IU/mL
  • AMH </= 0,1 ng/ml
  • No evidence of follicles > 4mm
  • Must have two ovaries of approximately equal volume.
  • Willingness to undergo further fertility treatment, including IVF if there is evidence of response
  • A transvaginal scan including Doppler for arteria ovarica will be performed previously to the surgical procedure.
Exclusion Criteria
  • Premature ovarian failure due to a genetic origin, such as Turner's Syndrome or chromosomal abnormality.
  • Oncological diseases (specially, skeletal system and blood).
  • Autoimmune diseases, for example, lupus erythematosus, etc.
  • Previous treatments including radiotherapy or chemotherapy.
  • Other conditions not suitable for surgical procedures and/or anesthesia.
  • Anticoagulant or antiaggregant treatment.
  • Acute and chronic infectious diseases.
  • Active substance abuse or dependence.
  • Major Mental health disorder.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
InterventionOvarian punctureThe cortex of selected ovary will be punctured up to ten times. In the surgical report, the surgeon will state how many punctures have been done.
InterventionHormonal blood TestThe cortex of selected ovary will be punctured up to ten times. In the surgical report, the surgeon will state how many punctures have been done.
InterventionTransvaginal ultrasoundThe cortex of selected ovary will be punctured up to ten times. In the surgical report, the surgeon will state how many punctures have been done.
Primary Outcome Measures
NameTimeMethod
Progesterone hormone evaluation after intervention.1 day

Progesterone hormone evaluation after intervention.

Follicle growth above 4 mm1 day

One or more follicles evaluated by transvaginal ultrasound. Defined by number of follicles growing, quantitative variable.

Anti-Müllerian hormone evaluation after intervention.1 day

Anti-Müllerian hormone evaluation after intervention.

Follicle-stimulating hormone evaluation after intervention.1 day

Follicle-stimulating hormone evaluation after intervention.

Luteinizing hormone evaluation after intervention.1 day

Luteinizing hormone evaluation after intervention.

Estradiol hormone evaluation after intervention.1 day

Estradiol hormone evaluation after intervention.

Spontaneous menstruation.1 day

Spontaneous menstruation.

Arteria ovarica doppler results.1 day

Arteria ovarica doppler results. Resistance index.

Secondary Outcome Measures
NameTimeMethod
Blastulation rate1 day

percentage of blastocysts per 2PN embryos

Aneuploidy rate1 day

percentage of aneuploid blastocysts per total blastocyst biopsied

Number of follicles1 day

Number of follicles

Number of oocytes retrieved1 day

Number of oocytes retrieved

Fertilization rate1 day

percentage of 2PN embryos per oocyte injected

Trial Locations

Locations (1)

ART Fertility Clinics LLC

🇦🇪

Abu Dhabi, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath